Celyad Oncology (NASDAQ:CYAD – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday, Zacks.com reports. The firm presently has a $2.25 price target on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 7.66% from the company’s […]
Related Keywords
Mont Saint Guibert , Waals Gewest , Belgium , , Exchange Commission , Wells Fargo Company , Zacks Investment Research , Celyad Oncology Company Profile Get Rating , Celyad Oncology , Get Rating , Investment Research , Oncology Company Profile , Nasdaq Cyad , Cyad , Medical , Upgrade ,
comparemela.com © 2020. All Rights Reserved.